Pathology group, Stavanger University Hospital.

Total RNA from the primary tumor will be fully sequenced on our Ion Proton (NGS). Tissue microRNA profiles from tumors sensitive to adjuvant chemotherapy will be compared with profiles from resistant tumors. In addition, samples will be checked for mutations especially in ER and other known oncogenes. Also,  the  Ki67-Adjusted Mitotic Score (KAMS), providing a measure of cell cycling kinetics within the proliferative population of cells, will be evaluated.  The centrosome amplification (as a measure for tumor heterogeneity and chromosomal instability) will be analyzed.

Back to Personalized Monitoring in Breast Cancer (PerMoBreCan).